Call Options

7 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$40.25 - $52.99 $784,875 - $1.03 Million
19,500 Added 3.3%
610,700 $25.4 Million
Q1 2024

May 15, 2024

SELL
$47.98 - $54.4 $7.95 Million - $9.01 Million
-165,700 Reduced 21.89%
591,200 $32.1 Million
Q4 2023

Feb 14, 2024

SELL
$48.48 - $57.85 $13 Million - $15.5 Million
-267,200 Reduced 26.09%
756,900 $38.8 Million
Q2 2023

Aug 14, 2023

SELL
$63.71 - $70.74 $66.8 Million - $74.2 Million
-1,048,400 Reduced 50.59%
1,024,100 $65.5 Million
Q1 2023

May 15, 2023

SELL
$65.71 - $74.53 $39.1 Million - $44.4 Million
-595,400 Reduced 22.32%
2,072,500 $144 Million
Q4 2022

Feb 14, 2023

BUY
$68.48 - $81.09 $80.2 Million - $94.9 Million
1,170,500 Added 78.17%
2,667,900 $192 Million
Q3 2022

Nov 14, 2022

BUY
$0.13 - $76.84 $86,138 - $50.9 Million
662,600 Added 79.37%
1,497,400 $106 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.